This brief outlines some perspectives from the Institute of Health Economics (IHE) based on what we have heard from government, public agencies, and industry, and seeks to summarize the key areas where further clarification and deliberation could be helpful.
As the Federal Government contemplates introducing an element of value-based pricing to the pharmaceutical industry regulatory framework, this report provides an overview of key theoretical and empirical material, to support informed engagement by all stakeholders in this important debate.
On November 1st, 2017, the Institute of Health Economics (IHE) hosted a pan-Canadian roundtable discussion regarding diabetes care and management in indigenous populations in Canada. This event was sponsored through an educational grant from Boehringer Ingelheim Canada, and was developed in consultation with an advisory committee including: Mr. Mehmood Alibhai (Boehringer Ingelheim…
This report on assisted reproductive technologies (ARTs) is a literature review and secondary analyses of administrative health data conducted to provide information on the direct health care costs associated with multiple pregnancies and the potential cost impact of ARTs in Alberta. It examines the impact of multiple pregnancies and Assistive Reproductive Technologies on health…